ArticleJournal of translational medicine2026
Exosome-delivered pepDCBLD2 promotes glucose metabolism to induce chemoresistance in colon cancer.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOxaliplatin is a standard treatment for colon cancer, but chemoresistance is a considerable challenge. Dysregulation of circRNAs is involved in cancer and translatomics has found that some circRNAs encode polypeptides.
methodsRibosome footprint profiling combined with circRNA sequencing was applied to screen circRNA with coding potential. Immunoprecipitation and mass spectrum were performed to explore the potential mechanism for regulating the downstream pathway. Ultracentrifugation and commercial kits were utilized to extract exosomes. Different kits were used to detect metabolic indexes. CCK-8, immunofluorescence and flow cytometry were conducted for the examination of oxaliplatin sensitivity. A xenograft model in NCG mice was established to demonstrate the pathway in vivo.
resultscircDCBLD2 could encode pepDCBLD2 through rolling circle translation. pepDCBLD2, instead of the circRNA itself, participated in competitive binding to ubiquitin protein ligases, and upregulated the expression of the parent gene DCBLD2. Additionally, exosomes from drug resistant cells transferred pepDCBLD2 to sensitive cells, where it intercellularly regulated the DCBLD2/ERK/PKM2 pathway. This enhanced the glucose metabolism and reactive oxygen species scavenging capacity, ultimately promoting chemoresistance.
conclusionsExosome-delivered pepDCBLD2 encoded by circDCBLD2 promoted glucose metabolism to induce oxaliplatin resistance through the DCBLD2/ERK/PKM2 axis, which might be a potential therapeutic target for future treatment of chemoresistant colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.